Rumors about the astonishing weight loss potential of Eli Lilly's triple hormone drug retatrutide have been circulating for months. The results of its Phase 3 clinical trial, just released by the drugmaker, amply justify the buzz. The company reports that "participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥30% weight loss, a level long associated with bariatric surgery."
Retatrutide is the latest compound to emerge from the revolution in hormonal treatment begun with the introduction of semaglutides like Ozempic in 2018 to treat Type 2 diabetes. Rebranded as Wegovy, the compound was approved for weight loss in June 2021.
